SBRI Healthcare Awards Funding for Phase 2 Development Program - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

SBRI Healthcare Awards Funding for Phase 2 Development Program



SBRI Healthcare, a Department of Health-funded initiative to develop innovative solutions that address unmet health needs, announced the three companies awarded phase 2 development funding in the SBRI Medicines Management competition.

From five companies awarded phase 1 funding in October 2012, three have demonstrated best value and greatest technical feasibility. At a typical cost of £250,000 (332,375 dollars) to £1million (1,329,500 dollars) each, the successful companies will be supported and fully funded to take their technologies through to commercialization and procurement.

Focused on effective medicines management, the current competition winners are developing innovative solutions to improve the number of patients taking prescribed medication. The three companies selected to receive phase 2 funding are:

Bespak Europe Ltd, (Cambridge, UK) , which is developing a new bolus drug delivery device using novel delivery technology.

Therakind Ltd, (London), which is developing a simple novel device that enables rapid and easy treatment of hypoglycaemia in child diabetes.

UMotif Ltd, (London), which is developing a patient-centered self-management and self-care platform with web and mobile apps that help people with Parkinson's Disease to track and manage their condition.

Source: SBRI Healthcare

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications

Click here